Dose-escalation single-center study of RGX-501 for the treatment of homozygous familial hypercholesterolemia

Trial Profile

Dose-escalation single-center study of RGX-501 for the treatment of homozygous familial hypercholesterolemia

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Jan 2018

At a glance

  • Drugs RGX 501 (Primary)
  • Indications Hypercholesterolaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 04 Jan 2018 According to a REGENXBIO media release, company expects to complete enrollment in this trial in mid-2018 and top-line data is expected in late 2018.
    • 08 Nov 2017 According to a REGENXBIO media release, review of data from the first cohort has been conducted by an independent DSMB, who has granted clearance to proceed to the next dosing cohort based on their assessment of the safety and tolerability data. The Company anticipates dosing of the second cohort in the trial to be initiated prior to year-end 2017.
    • 08 Nov 2017 According to a REGENXBIO media release, the company expects to provide updates from the trial are anticipated by year-end 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top